HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Enrico Ruffini Pier Luigi Filosso Paraskevas Lyberis Alberto Oliaro Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ruffini, E. Articles by Oliaro, A. Search for Related Content PubMed Articles by Ruffini, E. Articles by Oliaro, A. Related Collections Lung - cancer

---

Original Articles: General Thoracic

Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms

^a Department of Thoracic Surgery, University of Torino, Torino, Italy
^b Department of Pathology, University of Torino, Torino, Italy

Accepted for publication October 16, 2008.

^_* Address correspondence to Dr Ruffini, Thoracic Surgery Service, University of Torino, Ospedale Molinette, Dipartimento di Fisiopatologia Clinica, Sezione di Chirurgia Toracica, 3, Via Genova, Torino, 10126, Italy (Email: enrico.ruffini{at}unito.it).

Presented at the Forty-fourth Annual Meeting of The Society of Thoracic Surgeons, Fort Lauderdale, FL, Jan 28–30, 2008.

Background: Tumor-infiltrating lymphocytes (TIL) are considered important in anticancer immunosurveillance, although their role has not been clearly established yet. We examined prevalence, correlations, and prognostic significance of TIL among our patient population of resected lung neoplasms.

Methods: From 1993 to 2006, the presence of TIL was retrospectively evaluated in 1,290 patients operated on for primary lung neoplasms. Tumor-infiltrating lymphocytes were defined as those intraepithelial lymphocytes located within the cancer cell nests.

Results: Tumor-infiltrating lymphocytes were detected in 294 patients (23%). A significant difference was found between prevalence in non–small cell lung carcinomas versus neuroendocrine tumors (290 of 1,208, 24% versus 4 of 82, 5%; p = 0.0001). Prevalence was similar in adenocarcinomas, squamous-cell carcinomas, and large-cell anaplastic carcinomas. Logistic regression analysis indicates that TIL correlate with grading (odds ratio, 1.27; 95% confidence interval, 1.04 to 1.55; p = 0.02), tumor dimension (odds ratio, 0.86; 95% confidence interval, 0.79 to 0.94; p = 0.0008), and vascular invasion (odds ratio, 1.62; 95% confidence interval, 1.21 to 2.16; p = 0.0009). A not significantly better survival in the presence of TIL was observed overall (p = 0.20), becoming significant in squamous-cell carcinomas (p = 0.03). In patients with stage I disease, TIL is associated with a significant survival advantage in squamous-cell carcinomas (p = 0.03). The survival advantage increases with the duration of follow-up and is more evident after 4 to 6 years.

Conclusions: Tumor-infiltrating lymphocytes are observed in about one fourth of resected lung neoplasms: they are rare in neuroendocrine tumors. Tumor-infiltrating lymphocytes are more frequent in poorly differentiated tumors and in tumors with microscopic vascular invasion. The presence of TIL correlates with an improved survival in squamous cell carcinomas, particularly at early stage. The survival advantage increases with the duration of follow-up.